RARE

28.97

3.06% 0.86

Handel nachbörslich: 28.99 0.02 +0.07%

Ultragenyx Pharmaceutical Inc (RARE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RARE? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$28.11

Offen:

$28.43

24-Stunden-Volumen:

1.63M

Relative Volume:

0.91

Marktkapitalisierung:

$2.79B

Einnahmen:

$522.75M

Nettoeinkommen (Verlust:

$-558.99M

KGV:

-4.4776

EPS:

-6.47

Netto-Cashflow:

$-439.53M

1W Leistung:

+3.28%

1M Leistung:

-1.83%

6M Leistung:

-33.43%

1J Leistung:

-44.07%

1-Tages-Spanne:

$28.12

$29.37

1-Wochen-Bereich:

$27.00

$29.37

52-Wochen-Spanne:

$25.81

$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Firmenname

Ultragenyx Pharmaceutical Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (646)

Telefon

415-483-8800

Adresse

60 LEVERONI COURT, NOVATO, CA

Mitarbeiter

1,294

Twitter

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

RARE's Discussions on Twitter

Vergleichen Sie RARE mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RARE Ultragenyx Pharmaceutical Inc	28.97	2.71B	522.75M	-558.99M	-439.53M	-6.47
VRTX Vertex Pharmaceuticals Inc	395.92	99.42B	11.42B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	561.55	58.99B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	432.52	56.35B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	646.60	39.02B	3.05B	1.28B	-614.78M	19.58
ONC Beone Medicines Ltd Adr	307.51	34.25B	3.81B	-644.79M	-669.77M	-6.24

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-28	Fortgesetzt	H.C. Wainwright	Buy
2025-05-28	Eingeleitet	William Blair	Outperform
2024-06-06	Hochstufung	Goldman	Neutral → Buy
2024-04-22	Eingeleitet	RBC Capital Mkts	Outperform
2023-12-08	Eingeleitet	Wells Fargo	Overweight
2023-06-14	Fortgesetzt	Credit Suisse	Outperform
2023-06-06	Hochstufung	Evercore ISI	In-line → Outperform
2023-04-26	Eingeleitet	Cantor Fitzgerald	Overweight
2023-01-18	Fortgesetzt	Canaccord Genuity	Buy
2022-12-30	Fortgesetzt	H.C. Wainwright	Buy
2022-11-03	Hochstufung	Robert W. Baird	Neutral → Outperform
2022-10-13	Hochstufung	Guggenheim	Neutral → Buy
2022-08-01	Herabstufung	Evercore ISI	Outperform → In-line
2022-03-16	Hochstufung	Credit Suisse	Neutral → Outperform
2022-02-11	Hochstufung	JP Morgan	Neutral → Overweight
2021-09-30	Eingeleitet	H.C. Wainwright	Buy
2021-08-19	Eingeleitet	UBS	Sell
2021-07-15	Eingeleitet	Guggenheim	Neutral
2021-06-29	Hochstufung	BofA Securities	Neutral → Buy
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-05-06	Hochstufung	Citigroup	Neutral → Buy
2021-05-06	Hochstufung	Evercore ISI	In-line → Outperform
2021-04-26	Fortgesetzt	Credit Suisse	Neutral
2021-03-02	Fortgesetzt	Stifel	Buy
2021-02-12	Herabstufung	JP Morgan	Overweight → Neutral
2020-12-07	Herabstufung	Wedbush	Outperform → Neutral
2020-11-24	Fortgesetzt	Evercore ISI	In-line
2020-11-12	Herabstufung	BofA Securities	Buy → Neutral
2019-08-02	Fortgesetzt	Wedbush	Outperform
2019-03-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2019-02-22	Fortgesetzt	Raymond James	Outperform
2019-01-02	Herabstufung	Raymond James	Outperform → Mkt Perform
2018-11-08	Hochstufung	Citigroup	Sell → Neutral
2018-09-10	Eingeleitet	Morgan Stanley	Equal-Weight
2018-06-21	Herabstufung	Credit Suisse	Outperform → Neutral
2018-05-11	Hochstufung	Barclays	Equal Weight → Overweight
2018-05-10	Eingeleitet	Goldman	Neutral
2018-04-18	Hochstufung	SunTrust	Hold → Buy
2018-03-22	Fortgesetzt	Piper Jaffray	Overweight
2018-02-21	Bestätigt	Stifel	Buy
2018-01-22	Hochstufung	Evercore ISI	In-line → Outperform
2018-01-18	Eingeleitet	Credit Suisse	Outperform
2017-12-05	Bestätigt	Barclays	Equal Weight
2017-12-04	Hochstufung	Jefferies	Hold → Buy
2017-09-14	Hochstufung	Wedbush	Neutral → Outperform

Alle ansehen

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

11:46 AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx - Bluefield Daily Telegraph

11:46 AM

11:43 AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent

11:43 AM

Aug 12, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript - MSN

Aug 12, 2025

Aug 11, 2025

Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval - insights.citeline.com

Aug 11, 2025

Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 - Insider Monkey

Aug 11, 2025

Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace

Aug 11, 2025

Cantor Fitzgerald Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $105.00 - MarketBeat

Aug 11, 2025

Aug 10, 2025

Reversal indicators forming on Ultragenyx Pharmaceutical Inc. stockWeekly Growth Portfolio Performance Summary - Newser

Aug 10, 2025

Aug 09, 2025

Technical Charts Suggest Momentum Shift in Ultragenyx Pharmaceutical Inc.Potential Breakout Stock List Published This Week - beatles.ru

Aug 09, 2025

Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN

Aug 09, 2025

How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser

Aug 09, 2025

Signal strength of Ultragenyx Pharmaceutical Inc. stock in tech scannersHigh Conviction Stock Long-Term Summary - Newser

Aug 09, 2025

Aug 08, 2025

Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionFree Weekly Setup With 3x Return Potential - Newser

Aug 08, 2025

Ultragenyx's Q2 earnings exceed expectations, price target lowered to $128 by Canaccord. - AInvest

Aug 08, 2025

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance

Aug 08, 2025

Ultragenyx Pharmaceutical Analyst Ratings: Recent Assessments and Insights - AInvest

Aug 08, 2025

Aug 07, 2025

What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyEquity Portfolio Outlook and Performance Summary - Newser

Aug 07, 2025

RBC Capital Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE) - The Globe and Mail

Aug 07, 2025

FDA requests manufacturing changes for UX111 gene therapy - Sanfilippo Syndrome News

Aug 07, 2025

Ultragenyx Bets On Growth With Bullish Analyst Backing - Finimize

Aug 07, 2025

Ultragenyx Pharmaceutical Q2 2025 Earnings: Revenue Beats Expectations, Loss Narrows - AInvest

Aug 07, 2025

Ultragenyx Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Aug 07, 2025

Aug 06, 2025

‘Urgent need’ for treatment drives GTX-102 study enrollment - Angelman Syndrome News

Aug 06, 2025

Ultragenyx Pharmaceutical Inc. stock momentum explainedFree Proven Entry Plan With Low Risk Trade - Newser

Aug 06, 2025

Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges - TipRanks

Aug 06, 2025

‘On track to become profitable’: Marin County rare disorder drug maker narrows loss in Q2 - The North Bay Business Journal

Aug 06, 2025

Aspire Biopharma Holdings, Inc. shares rise 4.06% after-hours following Ultragenyx Pharmaceutical Inc. Q2 2025 earnings call. - AInvest

Aug 06, 2025

S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas - insights.citeline.com

Aug 06, 2025

Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating - TipRanks

Aug 06, 2025

Ultragenyx outlines $640M–$670M 2025 revenue target as clinical milestones advance - MSN

Aug 06, 2025

Ultragenyx: Q2 Earnings Snapshot - New Haven Register

Aug 06, 2025

Price action breakdown for Ultragenyx Pharmaceutical Inc.Long Term Equity Screener with Safety Metrics - Newser

Aug 06, 2025